Moxidectin + Pyrantel + Sarolaner
79 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 79 |
| Reports involving death | 10 |
| Case-fatality rate (reported events) | 1270.0% |
| Distinct species in reports | 2 |
| Distinct breeds in reports | 20 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 3 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Moxidectin + Pyrantel + Sarolaner Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 79 adverse event reports referencing Moxidectin + Pyrantel + Sarolaner, including 10 reports in which the animal died — a 1270.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Moxidectin, Pyrantel, Sarolaner. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Moxidectin + Pyrantel + Sarolaner reports are Dog (60 reports), Unknown (19 reports), with Dog accounting for the largest share. Within those species, Unknown (19), Dog (unknown) (6), Retriever - Labrador (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Moxidectin + Pyrantel + Sarolaner are Seizure NOS (21), Vomiting (11), Vocalisation (7), Diarrhoea (7). Of the 60 reports with a coded outcome, Recovered/Normal is the leading category at 30.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Moxidectin + Pyrantel + Sarolaner.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.